Edwards Lifesciences (EW) Competitors

Henry Schein (NASDAQ:HSIC) and Edwards Lifesciences (NYSE:EW) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk.

Which has more volatility & risk, HSIC or EW?

Henry Schein has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500.

Is HSIC or EW more profitable?

Edwards Lifesciences has a net margin of 72.96% compared to Henry Schein's net margin of 3.05%. Edwards Lifesciences' return on equity of 15.01% beat Henry Schein's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Henry Schein	3.05%	14.36%	5.52%
Edwards Lifesciences	72.96%	15.01%	11.56%

Do analysts prefer HSIC or EW?

Henry Schein currently has a consensus target price of $75.58, indicating a potential upside of 12.44%. Edwards Lifesciences has a consensus target price of $85.90, indicating a potential upside of 9.72%. Given Henry Schein's higher possible upside, equities research analysts plainly believe Henry Schein is more favorable than Edwards Lifesciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Henry Schein	0 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Edwards Lifesciences	1 Sell rating(s)	10 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.65

Does the media refer more to HSIC or EW?

In the previous week, Edwards Lifesciences had 10 more articles in the media than Henry Schein. MarketBeat recorded 33 mentions for Edwards Lifesciences and 23 mentions for Henry Schein. Henry Schein's average media sentiment score of 1.50 beat Edwards Lifesciences' score of 1.39 indicating that Henry Schein is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Henry Schein	17 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Edwards Lifesciences	22 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has stronger earnings & valuation, HSIC or EW?

Edwards Lifesciences has lower revenue, but higher earnings than Henry Schein. Edwards Lifesciences is trading at a lower price-to-earnings ratio than Henry Schein, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Henry Schein	$12.67B	0.64	$390M	$3.10	21.68
Edwards Lifesciences	$5.44B	8.45	$4.17B	$6.95	11.27

Do insiders & institutionals believe in HSIC or EW?

96.6% of Henry Schein shares are owned by institutional investors. Comparatively, 79.5% of Edwards Lifesciences shares are owned by institutional investors. 1.1% of Henry Schein shares are owned by insiders. Comparatively, 0.3% of Edwards Lifesciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Edwards Lifesciences beats Henry Schein on 11 of the 17 factors compared between the two stocks.